7733:TSEOlympus Corp. Analysis
Data as of 2026-03-13 - not real-time
¥1,310.50
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Olympus shares are trading just above a key support level while the broader trend remains bearish, as reflected by the price lagging behind its moving averages. The RSI is deep in oversold territory, suggesting a potential short‑term rebound, and the MACD has turned bullish, hinting at an early reversal.
Fundamentally, the company appears attractively priced: its price‑earnings multiple sits well below the industry average and the dividend yield is solid with a modest payout ratio, indicating sustainable income. Earnings per share are projected to rise sharply, and margins remain healthy, though the balance sheet shows a relatively high debt load that investors should monitor.
Risk factors include elevated 30‑day volatility and a sizable historical drawdown, but the stock’s beta is low, indicating limited market‑wide sensitivity. Liquidity is strong for a large‑cap Japanese firm, and regulatory and geographic exposures are moderate, while the dividend appears sustainable over the medium term.
Fundamentally, the company appears attractively priced: its price‑earnings multiple sits well below the industry average and the dividend yield is solid with a modest payout ratio, indicating sustainable income. Earnings per share are projected to rise sharply, and margins remain healthy, though the balance sheet shows a relatively high debt load that investors should monitor.
Risk factors include elevated 30‑day volatility and a sizable historical drawdown, but the stock’s beta is low, indicating limited market‑wide sensitivity. Liquidity is strong for a large‑cap Japanese firm, and regulatory and geographic exposures are moderate, while the dividend appears sustainable over the medium term.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price hovering near technical support
- RSI indicating oversold conditions
- MACD showing early bullish momentum
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- valuation multiples well below industry peers
- strong dividend yield with low payout ratio
- projected earnings growth and improving profit margins
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- stable cash flow generation and global market presence
- sustainable dividend policy
- defensive positioning within the medical‑devices sector
Key Metrics & Analysis
Financial Health
Revenue Growth3.90%
Profit Margin8.59%
P/E Ratio15.2
ROE11.25%
ROA6.10%
Debt/Equity30.75
P/B Ratio1.9
Op. Cash Flow¥123.5B
Free Cash Flow¥11.2B
Industry P/E26.2
Technical Analysis
TrendBearish
RSI27.0
Support¥1,302.50
Resistance¥1,965.00
MA 20¥1,461.08
MA 50¥1,757.09
MA 200¥1,840.53
MACDBullish
VolumeStable
Fear & Greed Index72.88
Valuation
Fair Value¥101.61
Target Price¥1,888.46
Upside/Downside44.10%
GradeUndervalued
TypeBlend
Dividend Yield2.29%
Risk Assessment
Beta0.60
Volatility55.59%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.